Skip to content

Catridecacog

NovoThirteen (catridecacog) is a protein pharmaceutical. Catridecacog was first approved as NovoThirteen on 2012-09-03. It has been approved in Europe to treat inherited blood coagulation disorders.
Trade Name NovoThirteen
Common Name Catridecacog
Indication inherited blood coagulation disorders
Drug Class
Catridecacog
Get full access now